Grifols S.A.
Buy, Hold or Sell?
Let's analyze Grifols together
I guess you are interested in Grifols S.A.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
I'm going to help you getting a better view of Grifols S.A.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
Get notifications about Grifols S.A.
I send you an email if I find something interesting about Grifols S.A..
1. Quick Overview
1.1. Quick analysis of Grifols (30 sec.)
1.2. What can you expect buying and holding a share of Grifols? (30 sec.)
How much money do you get?
What is your share worth?
+ What do you gain per year?
2. Detailed Analysis
2.1. Valuation of Grifols (5 min.)
2.2. Growth of Grifols (5 min.)
2.3. Financial Health of Grifols (5 min.)
3. Summary and Key Metrics
3.1. What can you expect buying and holding a share of Grifols?
Welcome investor! Grifols's management wants to use your money to grow the business. In return you get a share of Grifols.
First you should know what it really means to hold a share of Grifols. And how you can make/lose money.
Speculation
The Price per Share of Grifols is €9.048. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.
If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:
- The fundamentals: the financial health trends of Grifols.
- The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
- The book value: what is the market price compared to it's book value.
Investing
If you really want to invest in Grifols, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:
- You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €11.74. Based on the TTM, the Book Value Change Per Share is €-0.73 per quarter. Based on the YOY, the Book Value Change Per Share is €0.46 per quarter.
- You may receive quarterly/yearly dividend in the form of additional shares.
- You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
How much money are you going to get?
MRQ | TTM | YOY | 5Y | 10Y | ||||||
---|---|---|---|---|---|---|---|---|---|---|
€ | % of Price per Share | € | % of Price per Share | € | % of Price per Share | € | % of Price per Share | € | % of Price per Share | |
Usd Eps | 0.09 | 1.0% | 0.09 | 1.0% | 0.32 | 3.6% | 0.52 | 5.8% | 0.69 | 7.6% |
Usd Book Value Change Per Share | -0.76 | -8.4% | -0.76 | -8.4% | 0.48 | 5.3% | 1.02 | 11.3% | 0.91 | 10.0% |
Usd Dividend Per Share | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% | 0.19 | 2.1% | 0.26 | 2.9% |
Usd Total Gains Per Share | -0.76 | -8.4% | -0.76 | -8.4% | 0.48 | 5.3% | 1.21 | 13.4% | 1.17 | 12.9% |
Usd Price Per Share | 16.22 | - | 16.22 | - | 11.30 | - | 20.66 | - | 25.23 | - |
Price to Earnings Ratio | 176.94 | - | 176.94 | - | 35.08 | - | 67.11 | - | 51.39 | - |
Price-to-Total Gains Ratio | -21.26 | - | -21.26 | - | 23.37 | - | -480.34 | - | -216.86 | - |
Price to Book Ratio | 1.32 | - | 1.32 | - | 0.86 | - | 1.83 | - | 3.79 | - |
Price-to-Total Gains Ratio | -21.26 | - | -21.26 | - | 23.37 | - | -480.34 | - | -216.86 | - |
When do you get the money?
Usd Investment | |
---|---|
Usd Price Per Share | 9.495876 |
Number of shares | 105 |
Gains per Quarter | Trailing 12 Months | 5 Year |
---|---|---|
Usd Dividend Per Share | 0.00 | 0.19 |
Usd Book Value Change Per Share | -0.76 | 1.02 |
Usd Total Gains Per Share | -0.76 | 1.21 |
Gains per Quarter (105 shares) | -80.09 | 127.32 |
Gains per Year (105 shares) | -320.36 | 509.29 |
Years | Return on Investment (TTM) | Return on Investment (5Y) | ||||
---|---|---|---|---|---|---|
Dividend | Book Value gain | Total gains | Dividend | Book Value gain | Total gains | |
Broker costs | - | - | -10 | - | - | -10 |
1 | 0 | -320 | -330 | 79 | 430 | 499 |
2 | 0 | -641 | -650 | 158 | 861 | 1008 |
3 | 0 | -961 | -970 | 237 | 1291 | 1517 |
4 | 0 | -1281 | -1290 | 316 | 1721 | 2026 |
5 | 0 | -1602 | -1610 | 395 | 2151 | 2535 |
6 | 0 | -1922 | -1930 | 474 | 2582 | 3044 |
7 | 0 | -2243 | -2250 | 553 | 3012 | 3553 |
8 | 0 | -2563 | -2570 | 632 | 3442 | 4062 |
9 | 0 | -2883 | -2890 | 711 | 3872 | 4571 |
10 | 0 | -3204 | -3210 | 790 | 4303 | 5080 |
How sure are you?
Based on the past periods, how sure are you to get value out of your investment.
Linear %
Trailing 12 Months | 3Y | 5 Year | 10 Year | ALLTIME | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% | % | % | % | % | ||||||||||||||||
Earnings Per Share | 1.0 | 0.0 | 0.0 | 100.0% | 3.0 | 0.0 | 0.0 | 100.0% | 5.0 | 0.0 | 0.0 | 100.0% | 10.0 | 0.0 | 0.0 | 100.0% | 19.0 | 0.0 | 0.0 | 100.0% |
Book Value Change Per Share | 0.0 | 1.0 | 0.0 | 0.0% | 2.0 | 1.0 | 0.0 | 66.7% | 3.0 | 2.0 | 0.0 | 60.0% | 7.0 | 3.0 | 0.0 | 70.0% | 14.0 | 5.0 | 0.0 | 73.7% |
Dividend per Share | 0.0 | 0.0 | 1.0 | 0.0% | 2.0 | 0.0 | 1.0 | 66.7% | 4.0 | 0.0 | 1.0 | 80.0% | 9.0 | 0.0 | 1.0 | 90.0% | 17.0 | 0.0 | 2.0 | 89.5% |
Total Gains per Share | 0.0 | 1.0 | 0.0 | 0.0% | 2.0 | 1.0 | 0.0 | 66.7% | 3.0 | 2.0 | 0.0 | 60.0% | 8.0 | 2.0 | 0.0 | 80.0% | 15.0 | 4.0 | 0.0 | 78.9% |
3.2. Key Performance Indicators
The key performance indicators of Grifols S.A. compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Change Per Share | - | - | -0.727 | -0.727 | 0% | 0.460 | -258% | 0.976 | -174% | 0.865 | -184% |
Book Value Per Share | - | - | 11.740 | 11.740 | 0% | 12.467 | -6% | 11.204 | +5% | 8.234 | +43% |
Current Ratio | - | - | 2.786 | 2.786 | 0% | 2.379 | +17% | 2.609 | +7% | 2.737 | +2% |
Debt To Asset Ratio | - | - | 0.628 | 0.628 | 0% | 0.607 | +3% | 0.586 | +7% | 0.620 | +1% |
Debt To Equity Ratio | - | - | 2.311 | 2.311 | 0% | 2.133 | +8% | 1.948 | +19% | 1.940 | +19% |
Dividend Per Share | - | - | - | - | 0% | 0.001 | -100% | 0.179 | -100% | 0.249 | -100% |
Enterprise Value | - | - | -2443620828.055 | -2443620828.055 | 0% | -5178714825.620 | +112% | 3822850484.205 | -164% | 8783341426.417 | -128% |
Eps | - | - | 0.087 | 0.087 | 0% | 0.307 | -72% | 0.496 | -82% | 0.658 | -87% |
Ev To Ebitda Ratio | - | - | -2.067 | -2.067 | 0% | -4.450 | +115% | 2.632 | -179% | 7.463 | -128% |
Ev To Sales Ratio | - | - | -0.371 | -0.371 | 0% | -0.854 | +130% | 0.793 | -147% | 2.165 | -117% |
Free Cash Flow Per Share | - | - | -0.128 | -0.128 | 0% | -0.570 | +344% | 0.208 | -162% | 0.407 | -132% |
Free Cash Flow To Equity Per Share | - | - | 0.146 | 0.146 | 0% | -0.825 | +667% | 0.445 | -67% | 0.809 | -82% |
Gross Profit Margin | - | - | 0.911 | 0.911 | 0% | -2.203 | +342% | -0.129 | +114% | 0.435 | +109% |
Intrinsic Value_10Y_max | - | - | 1.085 | - | - | - | - | - | - | - | - |
Intrinsic Value_10Y_min | - | - | -6.281 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_max | - | - | 0.344 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_min | - | - | -0.231 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_max | - | - | 0.853 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_min | - | - | -1.044 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_max | - | - | 1.147 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_min | - | - | -2.233 | - | - | - | - | - | - | - | - |
Market Cap | 3819929807.616 | -175% | 10495371171.945 | 10495371171.945 | 0% | 7306483174.380 | +44% | 13426457484.205 | -22% | 16437020226.417 | -36% |
Net Profit Margin | - | - | 0.009 | 0.009 | 0% | 0.034 | -74% | 0.067 | -87% | 0.103 | -91% |
Operating Margin | - | - | 0.112 | 0.112 | 0% | 0.125 | -10% | 0.156 | -28% | 0.195 | -42% |
Operating Ratio | - | - | 0.888 | 0.888 | 0% | 0.884 | +0% | 0.851 | +4% | 0.807 | +10% |
Pb Ratio | 0.771 | -71% | 1.316 | 1.316 | 0% | 0.864 | +52% | 1.833 | -28% | 3.794 | -65% |
Pe Ratio | 103.590 | -71% | 176.943 | 176.943 | 0% | 35.080 | +404% | 67.107 | +164% | 51.391 | +244% |
Price Per Share | 9.048 | -71% | 15.455 | 15.455 | 0% | 10.770 | +44% | 19.682 | -21% | 24.037 | -36% |
Price To Free Cash Flow Ratio | -70.515 | +41% | -120.447 | -120.447 | 0% | -18.908 | -84% | 12.121 | -1094% | 37.799 | -419% |
Price To Total Gains Ratio | -12.449 | +41% | -21.265 | -21.265 | 0% | 23.369 | -191% | -480.341 | +2159% | -216.864 | +920% |
Quick Ratio | - | - | 0.629 | 0.629 | 0% | 0.710 | -11% | 1.416 | -56% | 1.396 | -55% |
Return On Assets | - | - | 0.003 | 0.003 | 0% | 0.010 | -71% | 0.021 | -87% | 0.038 | -93% |
Return On Equity | - | - | 0.010 | 0.010 | 0% | 0.034 | -70% | 0.068 | -85% | 0.115 | -91% |
Total Gains Per Share | - | - | -0.727 | -0.727 | 0% | 0.461 | -258% | 1.155 | -163% | 1.114 | -165% |
Usd Book Value | - | - | 8367123007.500 | 8367123007.500 | 0% | 8876192428.000 | -6% | 8006191981.300 | +5% | 5894591474.400 | +42% |
Usd Book Value Change Per Share | - | - | -0.763 | -0.763 | 0% | 0.483 | -258% | 1.024 | -174% | 0.907 | -184% |
Usd Book Value Per Share | - | - | 12.321 | 12.321 | 0% | 13.084 | -6% | 11.759 | +5% | 8.642 | +43% |
Usd Dividend Per Share | - | - | - | - | 0% | 0.001 | -100% | 0.188 | -100% | 0.261 | -100% |
Usd Enterprise Value | - | - | -2564580059.044 | -2564580059.044 | 0% | -5435061209.488 | +112% | 4012081583.173 | -164% | 9218116827.025 | -128% |
Usd Eps | - | - | 0.092 | 0.092 | 0% | 0.322 | -72% | 0.521 | -82% | 0.690 | -87% |
Usd Free Cash Flow | - | - | -91450281.500 | -91450281.500 | 0% | -405555136.500 | +343% | 149601397.300 | -161% | 292751832.950 | -131% |
Usd Free Cash Flow Per Share | - | - | -0.135 | -0.135 | 0% | -0.598 | +344% | 0.218 | -162% | 0.427 | -132% |
Usd Free Cash Flow To Equity Per Share | - | - | 0.153 | 0.153 | 0% | -0.866 | +667% | 0.467 | -67% | 0.849 | -82% |
Usd Market Cap | 4009016333.093 | -175% | 11014892044.956 | 11014892044.956 | 0% | 7668154091.512 | +44% | 14091067129.673 | -22% | 17250652727.625 | -36% |
Usd Price Per Share | 9.496 | -71% | 16.220 | 16.220 | 0% | 11.303 | +44% | 20.656 | -21% | 25.226 | -36% |
Usd Profit | - | - | 62251092.500 | 62251092.500 | 0% | 218588810.500 | -72% | 372911068.700 | -83% | 481070754.550 | -87% |
Usd Revenue | - | - | 6918279861.500 | 6918279861.500 | 0% | 6364133366.500 | +9% | 5883033330.900 | +18% | 5055689706.750 | +37% |
Usd Total Gains Per Share | - | - | -0.763 | -0.763 | 0% | 0.484 | -258% | 1.213 | -163% | 1.169 | -165% |
EOD | +4 -4 | MRQ | TTM | +0 -0 | YOY | +16 -24 | 5Y | +10 -30 | 10Y | +10 -30 |
3.3 Fundamental Score
Penke's Stock Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Price to Earnings Ratio (EOD) | Between | 0-15 | 103.590 | |
Price to Book Ratio (EOD) | Between | 0-1 | 0.771 | |
Net Profit Margin (MRQ) | Greater than | 0 | 0.009 | |
Operating Margin (MRQ) | Greater than | 0 | 0.112 | |
Quick Ratio (MRQ) | Greater than | 1 | 0.629 | |
Current Ratio (MRQ) | Greater than | 1 | 2.786 | |
Debt to Asset Ratio (MRQ) | Less than | 1 | 0.628 | |
Debt to Equity Ratio (MRQ) | Less than | 1 | 2.311 | |
Return on Equity (MRQ) | Greater than | 0.15 | 0.010 | |
Return on Assets (MRQ) | Greater than | 0.05 | 0.003 | |
Total | 5/10 (50.0%) |
3.4 Technical Score
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Rsi | Greater than | 50 | 59.389 | |
Ma 20 | Greater than | Ma 50 | 8.560 | |
Ma 50 | Greater than | Ma 100 | 8.927 | |
Ma 100 | Greater than | Ma 200 | 9.534 | |
Open | Greater than | Close | 8.856 | |
Total | 2/5 (40.0%) |
4. In-depth Analysis
4.1 About Grifols S.A.
- https://www.grifols.com
- 23000
- Avinguda de la Generalitat, 152, Barcelona, Spain, 08174
Google Maps Bing Maps
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Fundamental data was last updated by Penke on 2025-02-05 16:23:06.
4.2 In-depth Summary
4.2.1. Financial Health Summary
Compared to previous year | Compared to industry | |
---|---|---|
The company is not making a profit/loss. | ||
Using its assets, the company is inefficient in making profit. | ||
Using its investors money, the company is inefficient in making profit. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is operating less efficient. | ||
The company is less efficient in keeping operating costs low. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is able to pay all its short-term debts. | ||
The company is just not able to pay all its short-term debts with the most liquid assets. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is able to pay all its debts by selling its assets. | ||
The company is just not able to pay all its debts with equity. |
4.2.2. Valuation Summary
Compared to previous year | Compared to industry | |
---|---|---|
Based on the equity, the company is underpriced. | ||
Based on the earnings, the company is expensive. | ||
Based on how much money comes from the company's main activities, the company is expensive. |
4.3 Financial Health
4.3.1. Profitability
4.3.1 Profitability
4.3.1.1. Net Profit Margin
- Above 10% is considered healthy but always compare Grifols to the Drug Manufacturers - General industry mean.
- A Net Profit Margin of 0.9% means that €0.01 for each €1 in revenue is generated as profit.
Let's take a look of the Net Profit Margin trends of Grifols S.A.:
Trends
- The YOY is 3.4%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 6.7%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 10.3%. Compared to the 5Y term, the 10Y term is trending down. -2
4.3.1.2. Return on Assets
- Above 5% is considered healthy but always compare Grifols to the Drug Manufacturers - General industry mean.
- 0.3% Return on Assets means that Grifols generated €0.00 profit for each $1 in assets.
Let's take a look of the Return on Assets trends of Grifols S.A.:
Trends
- The YOY is 1.0%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 2.1%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 3.8%. Compared to the 5Y term, the 10Y term is trending down. -2
4.3.1.3. Return on Equity
- Above 15%-20% is considered healthy but always compare Grifols to the Drug Manufacturers - General industry mean.
- 1.0% Return on Equity means Grifols generated €0.01 for each €1 the owners (shareholders) invested.
Let's take a look of the Return on Equity trends of Grifols S.A.:
Trends
- The YOY is 3.4%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 6.8%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 11.5%. Compared to the 5Y term, the 10Y term is trending down. -2
4.3.2. Operating Efficiency of Grifols S.A..
4.3.2. Operating Efficiency
4.3.2.1. Operating Margin
- Measures how much profit Grifols makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
- Above 15% is considered healthy but always compare Grifols to the Drug Manufacturers - General industry mean.
- An Operating Margin of 11.2% means the company generated €0.11 for each €1 in revenue (before taxes).
Let's take a look of the Operating Margin trends of Grifols S.A.:
Trends
- The YOY is 12.5%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 15.6%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 19.5%. Compared to the 5Y term, the 10Y term is trending down. -2
4.3.2.2. Operating Ratio
- Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
- An Operation Ratio of 0.89 means that the operating costs are €0.89 for each €1 in net sales.
Let's take a look of the Operating Ratio trends of Grifols S.A.:
Trends
- The YOY is 0.884. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.851. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.807. Compared to the 5Y term, the 10Y term is trending up. -2
4.4.3. Liquidity of Grifols S.A..
4.4.3. Liquidity
4.4.3.1. Current Ratio
- Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
- A Current Ratio of 2.79 means the company has €2.79 in assets for each €1 in short-term debts.
Let's take a look of the Current Ratio trends of Grifols S.A.:
Trends
- The YOY is 2.379. Compared to the TTM, the mid term is trending up. +2
- The 5Y is 2.609. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is 2.737. Compared to the 5Y term, the 10Y term is trending down. -2
4.4.3.2. Quick Ratio
- Above 1 is considered healthy but always compare Grifols to the Drug Manufacturers - General industry mean.
- A Quick Ratio of 0.63 means the company can pay off €0.63 for each €1 in debt (using most liquid assets).
Let's take a look of the Quick Ratio trends of Grifols S.A.:
Trends
- The YOY is 0.710. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 1.416. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 1.396. Compared to the 5Y term, the 10Y term is trending up. +2
4.5.4. Solvency of Grifols S.A..
4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio
- Below 1 (100%) is considered healthy but always compare Grifols to Drug Manufacturers - General industry mean.
- A Debt to Asset Ratio of 0.63 means that Grifols assets are financed with 62.8% credit (debt) and the remaining percentage (100% - 62.8%) is financed by its owners/shareholders.
Let's take a look of the Debt to Asset Ratio trends of Grifols S.A.:
Trends
- The YOY is 0.607. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.586. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.620. Compared to the 5Y term, the 10Y term is trending down. +2
4.5.4.2. Debt to Equity Ratio
- Below 2 is considered healthy but always compare Grifols to the Drug Manufacturers - General industry mean.
- A Debt to Equity ratio of 231.1% means that company has €2.31 debt for each €1 in shareholders equity.
Let's take a look of the Debt to Equity Ratio trends of Grifols S.A.:
Trends
- The YOY is 2.133. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 1.948. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 1.940. Compared to the 5Y term, the 10Y term is trending up. -2
4.6. Market Valuation
4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio
- Above 15 is considered overpriced but always compare Grifols to the Drug Manufacturers - General industry mean.
- A PE ratio of 176.94 means the investor is paying €176.94 for every €1 in earnings.
Let's take a look of the Price to Earnings Ratio trends of Grifols S.A.:
Trends
- The YOY is 35.080. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 67.107. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 51.391. Compared to the 5Y term, the 10Y term is trending up. -2
4.6.2.2. Price To Free Cash Flow Ratio
Let's take a look of the Price To Free Cash Flow Ratio trends of Grifols S.A.:
- The EOD is -70.515. Based on how much money comes from the company's main activities, the company is expensive. -2
- The MRQ is -120.447. Based on how much money comes from the company's main activities, the company is expensive. -2
- The TTM is -120.447. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
- The YOY is -18.908. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 12.121. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 37.799. Compared to the 5Y term, the 10Y term is trending down. +2
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio
- At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
- A PB ratio of 1.32 means the investor is paying €1.32 for each €1 in book value.
Let's take a look of the Price to Book Ratio trends of Grifols S.A.:
Trends
- The YOY is 0.864. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 1.833. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 3.794. Compared to the 5Y term, the 10Y term is trending down. +2
4.6.2. Total Gains per Share
6. Financial Statements
6.1. Reversals in quarterly reports
I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.
2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Other Assets | 564,251 | 248,304 | 812,555 | 70,059 | 882,614 | -707,691 | 174,923 | -188,539 | -13,616 |
6.2. Latest Balance Sheet
Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.
Summary
As reported | |
---|---|
Total Liabilities | 13,468,569 |
Total Stockholder Equity | + 5,827,166 |
Total Assets | = 21,441,054 |
Assets
Total Current Assets
Long-term Assets
Property Plant Equipment | 4,192,363 |
Goodwill | 6,802,127 |
Long Term Investments | 565,105 |
Intangible Assets | 2,832,196 |
Long-term Assets Other | 292,063 |
Long-term Assets (as reported) | 14,989,149 |
---|---|
Long-term Assets (calculated) | 14,683,854 |
+/- | 305,295 |
Liabilities & Shareholders' Equity
Total Current Liabilities
Long-term Liabilities
Other
6.3. Balance Sheets Structured
Currency in EUR. All numbers in thousands.
Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 | 2005-12-31 | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 21,441,054 | 21,533,977 | 19,233,835 | 15,274,776 | 15,542,611 | 12,477,046 | 10,920,264 | 10,129,772 | 9,601,715 | 8,449,749 | 5,841,036 | 5,627,474 | 5,807,718 | 1,888,982 | 1,657,177 | 1,180,239 | 939,569 | 913,674 | 821,683 | |||||||||||||||||||
> Total Current Assets |
| 6,451,905 | 4,653,587 | 5,510,280 | 3,164,954 | 5,362,184 | 3,483,251 | 2,945,316 | 3,122,514 | 3,089,472 | 2,913,122 | 2,139,660 | 1,934,564 | 1,929,215 | 1,144,082 | 1,004,578 | 626,600 | 495,527 | 473,294 | 436,294 | |||||||||||||||||||
Cash And Cash Equivalents |
| 529,577 | 547,979 | 655,493 | 579,647 | 741,982 | 1,033,792 | 886,521 | 895,009 | 1,142,500 | 1,079,146 | 708,777 | 473,327 | 340,586 | 239,649 | 249,372 | 6,368 | 5,690 | 26,883 | 22,856 | |||||||||||||||||||
Short-term Investments |
| 116,143 | 43,256 | 2,029,107 | 10,861 | 1,727,429 | 822 | 702 | 957 | 509 | 476 | 232 | 0 | 16,904 | 12,946 | 8,217 | 6,657 | 7,080 | 6,232 | 661 | |||||||||||||||||||
Net Receivables |
| 810,980 | 754,820 | 495,476 | 504,200 | 470,495 | 401,573 | 385,265 | 528,518 | 477,803 | 608,328 | 462,655 | 441,788 | 528,595 | 282,994 | 252,630 | 231,806 | 200,472 | 188,868 | 158,724 | |||||||||||||||||||
Inventory |
| 3,459,277 | 3,201,357 | 2,259,354 | 2,002,281 | 2,342,590 | 1,949,360 | 1,629,293 | 1,642,931 | 1,431,391 | 1,194,057 | 946,913 | 998,644 | 1,030,341 | 527,865 | 484,462 | 373,098 | 270,659 | 235,475 | 249,545 | |||||||||||||||||||
Other Current Assets |
| 1,652,516 | 149,431 | 64,079 | 51,750 | 90,379 | 98,526 | 44,237 | 56,056 | 37,778 | 31,591 | 21,315 | 20,613 | 15,466 | 81,143 | 10,292 | 8,648 | 11,106 | 15,836 | 4,508 | |||||||||||||||||||
> Long-term Assets |
| 14,989,149 | 16,880,390 | 13,723,555 | 12,109,822 | 10,180,427 | 8,993,795 | 7,974,948 | 7,007,258 | 6,512,243 | 5,536,627 | 3,701,376 | 3,692,910 | 3,878,503 | 744,900 | 652,599 | 553,639 | 444,042 | 440,380 | 385,389 | |||||||||||||||||||
Property Plant Equipment |
| 4,192,363 | 4,168,489 | 3,343,154 | 3,002,803 | 2,863,403 | 1,951,983 | 1,760,053 | 1,809,852 | 1,644,402 | 1,147,782 | 840,238 | 810,107 | 775,869 | 434,131 | 371,705 | 301,009 | 201,332 | 184,993 | 186,621 | |||||||||||||||||||
Goodwill |
| 6,802,127 | 7,011,909 | 6,228,901 | 5,332,271 | 5,507,063 | 5,209,230 | 4,590,498 | 3,643,995 | 3,532,359 | 3,174,732 | 1,829,141 | 1,869,899 | 1,895,101 | 189,448 | 174,000 | 158,567 | 150,243 | 150,820 | 117,115 | |||||||||||||||||||
Long Term Investments |
| 565,105 | 2,548,892 | 2,359,975 | 2,067,177 | 143,984 | 228,820 | 259,063 | 232,421 | 78,137 | 58,651 | 39,130 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||
Intangible Assets |
| 2,832,196 | 2,949,147 | 1,636,950 | 1,557,650 | 1,433,534 | 1,385,537 | 1,269,342 | 1,195,302 | 1,161,572 | 1,068,361 | 946,435 | 969,095 | 1,008,307 | 78,299 | 69,385 | 57,756 | 57,223 | 60,850 | 48,718 | |||||||||||||||||||
Other Assets |
| -13,616 | 174,923 | 882,614 | 812,555 | 564,251 | 505,430 | 328,337 | 156,107 | 140,910 | 132,363 | 46,432 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||
> Total Liabilities |
| 13,468,569 | 13,076,433 | 11,086,800 | 8,554,721 | 8,696,843 | 7,780,442 | 7,286,299 | 6,401,794 | 6,300,325 | 5,786,861 | 3,733,832 | 3,746,733 | 4,142,724 | 1,181,592 | 1,078,649 | 698,960 | 555,403 | 545,322 | 765,736 | |||||||||||||||||||
> Total Current Liabilities |
| 2,315,604 | 1,955,847 | 3,474,312 | 1,335,138 | 1,366,558 | 1,257,321 | 977,987 | 1,071,763 | 1,053,006 | 1,079,711 | 715,296 | 592,865 | 646,077 | 423,126 | 299,043 | 317,538 | 316,576 | 282,764 | 252,405 | |||||||||||||||||||
Short-term Debt |
| 897,915 | 681,273 | 2,394,182 | 319,571 | 320,802 | 10,427 | 133,067 | 203,944 | 186,797 | 165,860 | 251,389 | 192,003 | 150,224 | 194,915 | 113,991 | 151,710 | 183,992 | 136,736 | 96,998 | |||||||||||||||||||
Short Long Term Debt |
| 790,814 | 578,917 | 2,345,615 | 276,929 | 276,397 | 264,851 | 129,122 | 200,085 | 188,073 | 154,567 | 2,730,711 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||
Accounts payable |
| 813,114 | 731,918 | 628,992 | 601,618 | 581,882 | 561,883 | 423,096 | 461,073 | 409,986 | 439,631 | 273,621 | 228,405 | 280,722 | 160,678 | 120,909 | 99,215 | 76,934 | 67,236 | 69,623 | |||||||||||||||||||
Other Current Liabilities |
| 550,859 | 470,016 | 407,599 | 389,969 | 399,597 | 632,316 | 372,259 | 358,037 | 400,563 | 339,602 | 167,219 | 157,462 | 210,440 | 63,361 | 60,885 | 50,251 | 51,880 | 78,792 | 85,784 | |||||||||||||||||||
> Long-term Liabilities |
| 11,152,965 | 11,120,586 | 7,612,488 | 7,219,583 | 7,330,285 | 6,523,121 | 6,308,312 | 5,330,031 | 5,247,319 | 4,707,150 | 3,018,536 | 3,153,868 | 3,496,647 | 758,466 | 779,606 | 381,422 | 238,827 | 262,558 | 513,331 | |||||||||||||||||||
Long term Debt Total |
| 0 | 9,068,852 | 7,179,483 | 6,885,043 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||
Other Liabilities |
| 0 | 2,051,734 | 682,364 | 627,755 | 544,198 | 502,613 | 430,134 | 648,935 | 675,473 | 601,091 | 536,531 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||
Deferred Long Term Liability |
| 0 | 1,622,641 | 633,240 | 575,515 | 331,808 | 287,205 | 232,345 | 70,620 | 45,137 | 45,262 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||
> Total Stockholder Equity |
| 5,827,166 | 6,129,938 | 6,096,643 | 5,108,392 | 4,822,119 | 4,225,554 | 3,629,079 | 3,721,481 | 3,296,203 | 2,658,123 | 2,101,262 | 1,876,768 | 1,662,507 | 693,040 | 566,371 | 480,029 | 383,185 | 367,944 | 55,826 | |||||||||||||||||||
Common Stock |
| 119,604 | 1,030,332 | 1,030,332 | 1,030,332 | 1,030,332 | 1,030,332 | 1,030,332 | 1,030,332 | 1,030,332 | 1,030,332 | 1,030,332 | 1,008,237 | 117,882 | 0 | 0 | 106,532 | 106,532 | 106,532 | 70,169 | |||||||||||||||||||
Retained Earnings |
| 59,315 | 208,279 | 182,803 | 618,546 | 488,318 | 459,895 | 539,714 | 422,548 | 412,530 | 384,309 | 276,796 | 256,686 | 50,307 | 115,513 | 147,972 | 0 | 0 | 45,394 | 25,556 | |||||||||||||||||||
Accumulated Other Comprehensive Income |
| 4,890,267 | 5,053,547 | 5,047,697 | 3,503,248 | 3,353,053 | 2,790,768 | 2,121,455 | 2,337,311 | 1,911,916 | 1,312,734 | 794,134 | 614,905 | 627,074 | 352,871 | 224,650 | 163,054 | 85,940 | 216,018 | -39,899 | |||||||||||||||||||
Capital Surplus |
| 0 | 910,728 | 910,728 | 910,728 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
6.4. Balance Sheets
Currency in EUR. All numbers in thousands.
6.5. Cash Flows
Currency in EUR. All numbers in thousands.
6.6. Income Statements
Currency in EUR. All numbers in thousands.